WHEELING -- A pharmaceutical corporation is suing over claims another company has infringed upon its drug patent.
Novartis Pharmaceuticals Corporation, Novartis Corporation, Novartis AG and Novartis Pharma AG filed a lawsuit June 26 in the U.S. District Court West Virginia Northern against Mylan Inc. and Mylan Pharmaceuticals Inc., citing patent infringement.
According to the complaint, Novartis Pharmaceuticals Corporation's EXJADE was approved by the FDA on Nov. 2, 2005, and the composition, dosing and administration of the drug is patented by Novartis. The lawsuit states in a May 13 letter, Mylan informed Novartis it intended to commercially manufacture and sell generic deferasirox oral tablets, which contain the same active ingredient, dosage and strength as EXJADE. Mylan is accused of infringement upon several patents.
Novartis is seeking judgment Mylan has infringed upon its patents and an order restraining Mylan from manufacturing and selling their drug.
Novartis is being represented in the case by attorneys James F. Companion and Yolonda G. Lambert of Schrader Byrd & Companion PLLC in Wheeling.
U.S. District Court West Virginia Northern Case No. 1:14-cv-00111-IMK